« Return to News | CROs/Service Providers

Sotio selects Chiltern International for phase III trial

Monday, March 18, 2013 12:13 PM

Sotio, a Czech Republic-based biotechnology company developing a next generation Active Cellular Immunotherapy, has selected Chiltern International to be the CRO that carries out the European part of its phase III global clinical trial titled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

Chiltern will be responsible for providing full-service management of the VIABLE phase III clinical trial in Europe. It will be the contracting party for 126 treatment centers in 17 European countries where a total of 750 patients are expected to participate in the trial. Chiltern will also be responsible for processing the data obtained during this clinical evaluation.

Dr. Jim Esinhart, CEO of Chiltern, said, "I am very pleased that we have been selected to manage this high profile trial. I believe it underscores the strengths and expertise of our global Oncology Therapeutic Area Team. We look forward to working in close partnership with Sotio to deliver a quality outcome."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.